Siegfried ERTL

International Business Unit Director

MDS: Treatment paradigms are changing

hemato-oncology, Tracking Studies, Syndicated Studies, Oncology

MyeloDysplastic Syndromes: our syndicated research will tell you why - and how - treatment paradigms are changing. Our results from first 2 waves conducted are available now and field is running for the 3rd wave. 

mRCC: promising new combinations lead to disruption in L1 and L2

Syndicated Studies, Oncology

Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of...